121 related articles for article (PubMed ID: 37889114)
1. PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
Pinton A; Courtois L; Doublet C; Cabannes-Hamy A; Andrieu G; Smith C; Balducci E; Cieslak A; Touzart A; Simonin M; Lhéritier V; Huguet F; Balsat M; Dombret H; Rousselot P; Spicuglia S; Macintyre E; Boissel N; Asnafi V
Clin Cancer Res; 2024 Jan; 30(1):94-105. PubMed ID: 37889114
[TBL] [Abstract][Full Text] [Related]
2. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia.
Wang Q; Qiu H; Jiang H; Wu L; Dong S; Pan J; Wang W; Ping N; Xia J; Sun A; Wu D; Xue Y; Drexler HG; Macleod RA; Chen S
Haematologica; 2011 Dec; 96(12):1808-14. PubMed ID: 21880637
[TBL] [Abstract][Full Text] [Related]
3. The Role of PHF6 in Hematopoiesis and Hematologic Malignancies.
Eisa YA; Guo Y; Yang FC
Stem Cell Rev Rep; 2023 Jan; 19(1):67-75. PubMed ID: 36008597
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia.
Mets E; Van Peer G; Van der Meulen J; Boice M; Taghon T; Goossens S; Mestdagh P; Benoit Y; De Moerloose B; Van Roy N; Poppe B; Vandesompele J; Wendel HG; Van Vlierberghe P; Speleman F; Rondou P
Haematologica; 2014 Aug; 99(8):1326-33. PubMed ID: 24895337
[TBL] [Abstract][Full Text] [Related]
5. [Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].
Kong JY; Zong LH; Pu Y; Liu Y; Kong X; Li MY; Zhang J; Song BQ; Xue SL; Tang XW; Qiu HY; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):649-653. PubMed ID: 37803838
[No Abstract] [Full Text] [Related]
6. Somatic mutation of PHF6 gene in T-cell acute lymphoblatic leukemia, acute myelogenous leukemia and hepatocellular carcinoma.
Yoo NJ; Kim YR; Lee SH
Acta Oncol; 2012 Jan; 51(1):107-11. PubMed ID: 21736506
[TBL] [Abstract][Full Text] [Related]
7. ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Rahmani NE; Ramachandra N; Sahu S; Gitego N; Lopez A; Pradhan K; Bhagat TD; Gordon-Mitchell S; Pena BR; Kazemi M; Rao K; Giricz O; Maqbool SB; Olea R; Zhao Y; Zhang J; Dolatshad H; Tittrea V; Tatwavedi D; Singh S; Lee J; Sun T; Steidl U; Shastri A; Inoue D; Abdel-Wahab O; Pellagatti A; Gavathiotis E; Boultwood J; Verma A
Blood Cancer J; 2021 Sep; 11(9):157. PubMed ID: 34548471
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL.
Touzart A; Lengliné E; Latiri M; Belhocine M; Smith C; Thomas X; Spicuglia S; Puthier D; Pflumio F; Leguay T; Graux C; Chalandon Y; Huguet F; Leprêtre S; Ifrah N; Dombret H; Macintyre E; Hunault M; Boissel N; Asnafi V
Clin Cancer Res; 2019 Apr; 25(8):2483-2493. PubMed ID: 30659025
[TBL] [Abstract][Full Text] [Related]
9. PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia.
Tsai HI; Wu Y; Huang R; Su D; Wu Y; Liu X; Wang L; Xu Z; Pang Y; Sun C; He C; Shu F; Zhu H; Wang D; Cheng F; Huang L; Chen H
Acta Pharm Sin B; 2022 Apr; 12(4):1913-1927. PubMed ID: 35847518
[TBL] [Abstract][Full Text] [Related]
10. Structural and functional insights into the human Börjeson-Forssman-Lehmann syndrome-associated protein PHF6.
Liu Z; Li F; Ruan K; Zhang J; Mei Y; Wu J; Shi Y
J Biol Chem; 2014 Apr; 289(14):10069-83. PubMed ID: 24554700
[TBL] [Abstract][Full Text] [Related]
11. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia.
Quagliano A; Gopalakrishnapillai A; Barwe SP
Leuk Res; 2017 May; 56():36-43. PubMed ID: 28171800
[TBL] [Abstract][Full Text] [Related]
13. Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia.
van Dijk AD; Hoff FW; Qiu YH; Chandra J; Jabbour E; de Bont ESJM; Horton TM; Kornblau SM
Clin Epigenetics; 2021 Jan; 13(1):21. PubMed ID: 33509276
[TBL] [Abstract][Full Text] [Related]
14. A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia.
Hu RH; Su L; Lan XX; Chang XL; Hui WH; Guo YX; Zhao H; Zhang Y; Sun WL
Anticancer Drugs; 2023 Mar; 34(3):344-350. PubMed ID: 36622759
[TBL] [Abstract][Full Text] [Related]
15. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
Kuang SQ; Fang Z; Zweidler-McKay PA; Yang H; Wei Y; Gonzalez-Cervantes EA; Boumber Y; Garcia-Manero G
PLoS One; 2013; 8(4):e61807. PubMed ID: 23637910
[TBL] [Abstract][Full Text] [Related]
17.
Wendorff AA; Quinn SA; Rashkovan M; Madubata CJ; Ambesi-Impiombato A; Litzow MR; Tallman MS; Paietta E; Paganin M; Basso G; Gastier-Foster JM; Loh ML; Rabadan R; Van Vlierberghe P; Ferrando AA
Cancer Discov; 2019 Mar; 9(3):436-451. PubMed ID: 30567843
[TBL] [Abstract][Full Text] [Related]
18. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.
Ntziachristos P; Tsirigos A; Van Vlierberghe P; Nedjic J; Trimarchi T; Flaherty MS; Ferres-Marco D; da Ros V; Tang Z; Siegle J; Asp P; Hadler M; Rigo I; De Keersmaecker K; Patel J; Huynh T; Utro F; Poglio S; Samon JB; Paietta E; Racevskis J; Rowe JM; Rabadan R; Levine RL; Brown S; Pflumio F; Dominguez M; Ferrando A; Aifantis I
Nat Med; 2012 Feb; 18(2):298-301. PubMed ID: 22237151
[TBL] [Abstract][Full Text] [Related]
19. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression.
Yuan S; Wang X; Hou S; Guo T; Lan Y; Yang S; Zhao F; Gao J; Wang Y; Chu Y; Shi J; Cheng T; Yuan W
Leukemia; 2022 Feb; 36(2):370-382. PubMed ID: 34465864
[TBL] [Abstract][Full Text] [Related]
20. The depletion of PHF6 decreases the drug sensitivity of T-cell acute lymphoblastic leukemia to prednisolone.
Xiang J; Wang G; Xia T; Chen Z
Biomed Pharmacother; 2019 Jan; 109():2210-2217. PubMed ID: 30551478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
